According to the presented data, by targeting cellular metabolism via glycolysis inhibitors (2-DG, WP1122) and modulating cellular transcription processes with HDAC inhibitors (NaBt, NaVPA), we can eliminate GBM cells. This evidence concerns the gene HDAC9 and glioblastoma.